Clinical effect of deep brain stimulation with subthalamic nucleus combined with low dose of dopaminazide in treatment of Parkinson's disease and its influence on anxiety,depression and sleep disorders
Objective:To explore the clinical efficacy of subthalamic nucleus deep brain stimulation(STN-DBS)combined with low dose of dopaminazide in the treatment of Parkinson's disease(PD)and its influence on anxiety,depression and sleep disorders.Methods:A total of 81 PD patients were selected as observation objects and randomly divided into study group(n=41)and control group(n=40)according to their willingness to treat.The control group was given dopasehydrazine treatment.The research group was treated with STN-DBS on the basis of the treatment of the control group,and the Parkinson's Disease Comprehensive Assessment Scale(UPDRS)score,Hamilton Anxiety Scale(HAMA)score,Hamilton Depression Scale(HAMA)score before treatment and 6 months after treatment in the two groups were observed.Scale(HAMD-17)score,Parkinson's Sleep Scale(PDSS)score,Pittsburgh Sleep Quality Index(PSQI)score,drug dose changes and adverse reactions.Results:The total clinical effective rate of the study group was 95.12％higher than that of the control group(P＜0.05);the UPDRS-Ⅰ,UPDRS-Ⅱ,UPDRS-Ⅲ scores,HAMD-17 scores,HAMA scores,The PDSS score and PSQI score were significantly lower than those before treatment,and the indexes in the study group were significantly lower than those in the control group(P＜0.01).After treatment in the study group,the equivalent dose of levodopa in patients could be reduced.Conclusion:STN-DBS combined with dopasehydrazine is effective in the treatment of PD.It can improve patients'exercise ability,improve activities of daily living,improve anxiety,depression and sleep disorders,and reduce the dose of anti-PD drugs and adverse drug reactions.
Parkinson's diseasesubthalamic nucleus deep brain stimulationanxietydepressionsleep disorders
NETL
NSTL
万方数据
维普
